source
- GSK halts camlipixant development after mixed Phase 3 results curb blockbuster hopesGSK announced it is stopping work on camlipixant, a P2X3 receptor antagonist it bought when acquiring Bellus Health in 2023, after the drug produced mixed results in two Phase 3 chronic cough trial…
- Bolton Medical Issues Urgent Recall of Relay Pro Thoracic Stent Graft Over Unclasping FaultBolton Medical announced an urgent Class I recall of its Relay Pro Thoracic Stent Graft System, specifically the non-bare stent configuration 32 mm and larger. The recall was triggered because the…